2 weeks ago
Telangana Aims to Be India's Life Sciences Innovation Capital
Telangana is a state in India where lots of medicines are made.
It is already famous for making medicines and vaccines for the whole world.
Now, the people in charge there want to do more than just make medicines.
They want to be the best at inventing new medicines too.
They have a big plan to bring in 25 billion dollars and create more than five lakh new jobs.
That is a lot of money and a lot of jobs!
They want to make special new treatments, like medicines made from living cells.
The leaders say India also needs to make more of the ingredients used in medicines at home.
A big medicine show called CPHI & PMEC India is coming in November.
It will happen in Delhi and nearby Greater Noida.
Telangana officials say the state, already a pharma manufacturing and vaccine hub, now seeks to become India's life sciences innovation capital.
The Next-Gen Life Sciences Policy 2026-2030 targets USD 25 billion in investments and over five lakh jobs in five years.
Focus areas include biologics, biosimilars, cell and gene therapies where biology, chemistry, and technology converge.
Industry experts stress the need for more R&D investment, API backward integration, and reducing dependence on imported key starting materials.
CPHI & PMEC India 2026 is scheduled for November in Delhi-NCR, with CPHI India at IICC Yashobhoomi, Dwarka (Nov 23-25) and PMEC India at IEML, Greater Noida (Nov 24-26).
- Who
- Government of Telangana officials, including CEO Sarvesh Singh, and leaders from India's pharmaceutical and life sciences industry.
- What
- Experts outlined ambitions and strategies for Telangana to become India's life sciences innovation capital, moving beyond manufacturing.
- Where
- Hyderabad, with the upcoming CPHI & PMEC India 2026 event in Delhi-NCR (Dwarka and Greater Noida).
- When
- At a recent industry event held ahead of the 19th edition of CPHI & PMEC India 2026, scheduled for November 23-26.
- Why
- To move up the value chain beyond manufacturing and build competitiveness in innovation, biologies, and domestic API capacity.
Key facts
- Investment target
- USD 25 billion under Next-Gen Life Sciences Policy 2026-2030
- Jobs target
- Over five lakh jobs in five years
- India pharma market target
- USD 130 billion by 2030
- Focus areas
- Biologics, biosimilars, cell and gene therapies
- CPHI India 2026 dates/venue
- November 23-25, IICC, Yashobhoomi, Dwarka
- PMEC India 2026 dates/venue
- November 24-26, IEML, Greater Noida
- Event edition
- 19th edition of CPHI & PMEC India
Quotes
Sarvesh Singh
CEO of Life Sciences and Pharma, Government of Telangana
“The capability to manufacture is well established; the priority now is to strengthen competitiveness, reduce dependence on imported key starting materials and intermediates, and build greater depth across the domestic value chain.”
deccanchronicle.com
“Through our Next‑Gen Life Sciences Policy 2026‑2030, we aim to attract USD 25 billion in investments and create more than five lakh jobs over the next five years.”
deccanchronicle.com
Sources
Related news
Telangana Bets on Talent and Technology for Manufacturing Growth
Telangana CM: investment, infrastructure, jobs top priorities
Uttam Invites Global Investment to Drive Telangana Growth
Bhatti highlights Telangana's investment potential in the US
Bharat Life Sciences Award Celebrates India's Scientific Excellence Ecosystem
Telangana Announces 'Invest Telangana' Summit Focused on Defence, Aerospace, Pharma
UP BLO Headmaster Dies by Suicide
